CZ253395A3 - Method of controlled activation and degradation of factor vii during purification process - Google Patents

Method of controlled activation and degradation of factor vii during purification process Download PDF

Info

Publication number
CZ253395A3
CZ253395A3 CZ952533A CZ253395A CZ253395A3 CZ 253395 A3 CZ253395 A3 CZ 253395A3 CZ 952533 A CZ952533 A CZ 952533A CZ 253395 A CZ253395 A CZ 253395A CZ 253395 A3 CZ253395 A3 CZ 253395A3
Authority
CZ
Czechia
Prior art keywords
fvii
buffer
nacl
activation
degradation
Prior art date
Application number
CZ952533A
Other languages
Czech (cs)
English (en)
Inventor
Tony Jorgensen
Anders H Pedersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CZ253395A3 publication Critical patent/CZ253395A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CZ952533A 1993-03-31 1994-03-24 Method of controlled activation and degradation of factor vii during purification process CZ253395A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93382A DK38293D0 (da) 1993-03-31 1993-03-31 Fremstilling af proteiner

Publications (1)

Publication Number Publication Date
CZ253395A3 true CZ253395A3 (en) 1996-01-17

Family

ID=8092871

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ952533A CZ253395A3 (en) 1993-03-31 1994-03-24 Method of controlled activation and degradation of factor vii during purification process

Country Status (16)

Country Link
US (1) US5700914A (enExample)
EP (1) EP0691984A1 (enExample)
JP (1) JPH08508264A (enExample)
CN (1) CN1039231C (enExample)
AU (1) AU677309B2 (enExample)
CA (1) CA2159313A1 (enExample)
CZ (1) CZ253395A3 (enExample)
DK (1) DK38293D0 (enExample)
FI (1) FI954649A0 (enExample)
HU (1) HUT72712A (enExample)
IL (1) IL109164A0 (enExample)
NO (1) NO953883L (enExample)
PL (1) PL310887A1 (enExample)
TW (1) TW278079B (enExample)
WO (1) WO1994022905A1 (enExample)
ZA (1) ZA941956B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
SI1308455T1 (sl) † 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
CA2519020A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Method for the production of gla-residue containing serine proteases
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
DE602004025100D1 (de) * 2003-05-23 2010-03-04 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
WO2005054275A2 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor vii solutions to remove virus
CA2549593C (en) * 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
AU2005318106B2 (en) * 2004-12-23 2011-11-03 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest
DE602006015907D1 (de) * 2005-01-14 2010-09-16 Bayer Healthcare Llc Verfahren zur reinigung von factor vii
EP1907540B1 (en) * 2005-07-22 2012-12-19 Bayer HealthCare LLC In-solution activation of factor vii
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2007073486A2 (en) * 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
BR112015008666B1 (pt) 2012-10-17 2020-04-07 Procter & Gamble produto extensível para tratamento dental e método de aplicação de um ativo para tratamento bucal
US11059857B2 (en) 2016-12-22 2021-07-13 Km Biologics Co., Ltd. Chromatographic method for collecting blood coagulation factor VII with high yield

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Also Published As

Publication number Publication date
HU9502846D0 (en) 1995-12-28
NO953883D0 (no) 1995-09-29
AU6423994A (en) 1994-10-24
CN1039231C (zh) 1998-07-22
PL310887A1 (en) 1996-01-08
US5700914A (en) 1997-12-23
HUT72712A (en) 1996-05-28
TW278079B (enExample) 1996-06-11
ZA941956B (en) 1994-09-30
FI954649A7 (fi) 1995-09-29
IL109164A0 (en) 1994-06-24
FI954649L (fi) 1995-09-29
FI954649A0 (fi) 1995-09-29
CA2159313A1 (en) 1994-10-13
NO953883L (no) 1995-11-28
WO1994022905A1 (en) 1994-10-13
AU677309B2 (en) 1997-04-17
JPH08508264A (ja) 1996-09-03
CN1121723A (zh) 1996-05-01
EP0691984A1 (en) 1996-01-17
DK38293D0 (da) 1993-03-31

Similar Documents

Publication Publication Date Title
CZ253395A3 (en) Method of controlled activation and degradation of factor vii during purification process
AU740753C (en) Improved methods for processing activated protein C
Stenflo Structure and function of protein C
US20080214462A1 (en) FIX-Mutant Proteins for Hemophilia B Treatment
Josic et al. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C
AU2008209986A1 (en) FVIII-independent FIX-mutant proteins for hemophilia A treatment
PL191778B1 (pl) Analog czynnika X Δ , rekombinowany kwas nukleinowy, wektor, komórka, kompozycje i ich zastosowania oraz sposób wytwarzania kompozycji
US6958322B1 (en) Factor X analog with an improved ability to be activated
Himmelspach et al. Recombinant human factor X: high yield expression and the role of furin in proteolytic maturation in vivo and in vitro
RU2167936C2 (ru) Способ минимизации деградации активированного протеина с (варианты), стабилизированная композиция активированного протеина с
US5510248A (en) Stable recombinant meizothrombin-like polypeptides
AU769144B2 (en) Improved methods for processing activated protein C
AU4409399A (en) Human protein c polypeptide
CZ373799A3 (cs) Zlepšené způsoby zpracování aktivovaného proteinu C
Hung Structural-functional Studies of the Non-enzymatic Domains of Prothrombin
Su Localization of ligand-binding exosites in the catalytic domain of FXIa and determination of the roles of calcium and the heavy chain of FXIa in fix activation by FXIa
EP1557463A1 (en) Improved methods for processing activated protein C
Boskovic Studies of prothrombinase-catalyzed activation of bovine prothrombin.
SK124699A3 (en) Activated vitamin k-dependent blood factor and method for the production thereof
HK1219285A1 (en) Purification method for vitamin k dependent proteins by anion exchange chromatography
HK1219285B (en) Purification method for vitamin k dependent proteins by anion exchange chromatography